Literature DB >> 4006366

Mexiletine kinetics in healthy subjects taking cimetidine.

A Klein, M Sami, K Selinger.   

Abstract

Cimetidine, a commonly used H2-receptor antagonist, was found to interact adversely with many drugs, including class I antiarrhythmics such as lidocaine and quinidine. To test the effect of cimetidine on the kinetics of mexiletine, a class I antiarrhythmic similar to lidocaine, the absorption and disposition of mexiletine were followed in six healthy subjects before and after 1 week of cimetidine, 300 mg by mouth four times a day. Cimetidine did not alter the distribution and elimination of mexiletine, as shown by similar mean kinetics including total body clearance, AUC, and the elimination t1/2 before and after cimetidine treatment. Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml). We conclude that cimetidine does not alter the disposition of oral mexiletine in normal subjects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006366     DOI: 10.1038/clpt.1985.109

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

3.  Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Authors:  Laurence Gabriel; Michel Tod; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 5.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

6.  Kinetics of oral and intravenous mexiletine: lack of effect of cimetidine and ranitidine.

Authors:  N H Brockmeyer; H Breithaupt; W Ferdinand; M von Hattingberg; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 8.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine.

Authors:  J Bonde; L E Pedersen; E Nygaard; T Ramsing; H R Angelo; J P Kampmann
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.